These findings demonstrated that ATT suppresses the pathology of RA‐FLSs by modulating METTL3‐mediated m6A modification of ICAM2 mRNA, thereby leading to inhibition of ICAM2/PI3K/AKT/p300 pathway. The gene discussed is EP300; the disease is rheumatoid arthritis.